Logo image of CLVS

CLOVIS ONCOLOGY INC (CLVS) Stock Fundamental Analysis

NASDAQ:CLVS - Nasdaq - US1894641000 - Common Stock - Currency: USD

0.0812  0 (-5.58%)

After market: 0.078 0 (-3.94%)

Fundamental Rating

1

Overall CLVS gets a fundamental rating of 1 out of 10. We evaluated CLVS against 556 industry peers in the Biotechnology industry. Both the profitability and financial health of CLVS have multiple concerns. While showing a medium growth rate, CLVS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLVS has reported negative net income.
CLVS had a negative operating cash flow in the past year.
CLVS Yearly Net Income VS EBIT VS OCF VS FCFCLVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -100M -200M -300M -400M

1.2 Ratios

The profitability ratios for CLVS are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLVS Yearly ROA, ROE, ROICCLVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 2K 4K 6K 8K

1.3 Margins

CLVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLVS Yearly Profit, Operating, Gross MarginsCLVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100K -200K -300K

More info and screens

0

2. Health

2.1 Basic Checks

CLVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLVS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for CLVS is higher compared to a year ago.
CLVS Yearly Shares OutstandingCLVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
CLVS Yearly Total Debt VS Total AssetsCLVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -16.18, we must say that CLVS is in the distress zone and has some risk of bankruptcy.
CLVS's Altman-Z score of -16.18 is on the low side compared to the rest of the industry. CLVS is outperformed by 87.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.18
ROIC/WACCN/A
WACC2.06%
CLVS Yearly LT Debt VS Equity VS FCFCLVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M -200M 400M -400M 600M

2.3 Liquidity

CLVS has a Current Ratio of 0.14. This is a bad value and indicates that CLVS is not financially healthy enough and could expect problems in meeting its short term obligations.
CLVS has a Current ratio of 0.14. This is amonst the worse of the industry: CLVS underperforms 96.24% of its industry peers.
A Quick Ratio of 0.12 indicates that CLVS may have some problems paying its short term obligations.
CLVS has a worse Quick ratio (0.12) than 96.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.12
CLVS Yearly Current Assets VS Current LiabilitesCLVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.04% over the past year.
The Revenue for CLVS has decreased by -14.78% in the past year. This is quite bad
Measured over the past years, CLVS shows a very strong growth in Revenue. The Revenue has been growing by 331.02% on average per year.
EPS 1Y (TTM)36.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.36%
Revenue 1Y (TTM)-14.78%
Revenue growth 3Y15.96%
Revenue growth 5Y331.02%
Sales Q2Q%-19.13%

3.2 Future

Based on estimates for the next years, CLVS will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.36% on average per year.
CLVS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.17% yearly.
EPS Next Y28.29%
EPS Next 2Y28.47%
EPS Next 3Y21.43%
EPS Next 5Y9.36%
Revenue Next Year-14%
Revenue Next 2Y1.79%
Revenue Next 3Y3.93%
Revenue Next 5Y4.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CLVS Yearly Revenue VS EstimatesCLVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
CLVS Yearly EPS VS EstimatesCLVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLVS. In the last year negative earnings were reported.
Also next year CLVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLVS Price Earnings VS Forward Price EarningsCLVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLVS Per share dataCLVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

CLVS's earnings are expected to grow with 21.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.47%
EPS Next 3Y21.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLVS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLOVIS ONCOLOGY INC

NASDAQ:CLVS (12/20/2022, 9:19:57 PM)

After market: 0.078 0 (-3.94%)

0.0812

0 (-5.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2022-11-09/bmo
Earnings (Next)02-21 2023-02-21
Inst Owners0%
Inst Owner Change-98.86%
Ins Owners5.92%
Ins Owner Change0%
Market Cap11.77M
Analysts42.86
Price Target2.04 (2412.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.55%
Min EPS beat(2)-18.6%
Max EPS beat(2)7.49%
EPS beat(4)3
Avg EPS beat(4)1.65%
Min EPS beat(4)-18.6%
Max EPS beat(4)17.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.2%
Min Revenue beat(2)-14.9%
Max Revenue beat(2)-9.51%
Revenue beat(4)0
Avg Revenue beat(4)-9.99%
Min Revenue beat(4)-14.9%
Max Revenue beat(4)-6.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)9.3%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.44%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0.92
BVpS-2.88
TBVpS-3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.12
Altman-Z -16.18
F-Score3
WACC2.06%
ROIC/WACCN/A
Cap/Depr(3y)116.85%
Cap/Depr(5y)382.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.36%
EPS Next Y28.29%
EPS Next 2Y28.47%
EPS Next 3Y21.43%
EPS Next 5Y9.36%
Revenue 1Y (TTM)-14.78%
Revenue growth 3Y15.96%
Revenue growth 5Y331.02%
Sales Q2Q%-19.13%
Revenue Next Year-14%
Revenue Next 2Y1.79%
Revenue Next 3Y3.93%
Revenue Next 5Y4.17%
EBIT growth 1Y11.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.44%
EBIT Next 3Y22.73%
EBIT Next 5Y8.67%
FCF growth 1Y36.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.2%
OCF growth 3YN/A
OCF growth 5YN/A